{"id":"W4382198144","doi":"10.1200/jco.22.02887","title":"Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"National Center for Advancing Translational Sciences; Regeneron Pharmaceuticals; National Institutes of Health; Astellas Pharma; G1 Therapeutics; Pharmacyclics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Clovis Oncology; Sanofi; Exelixis; Advanced Accelerator Applications; Endocyte; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Seagen; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Neutropenia; Internal medicine; Rash; Oncology; Urothelial cancer; Adverse effect; Metastatic Urothelial Carcinoma; Cisplatin; Cancer; Nausea; Chemotherapy; Bladder cancer; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008843958,0.000346871,0.002311931,0.0003144221,0.00005417485,0.00001660981,0.000205381,0.0002124009,0.0005113484],"category_scores_gemma":[0.0009321283,0.0001656309,0.0002019865,0.0008383399,0.0002144179,0.0002140941,0.00004293333,0.0008244307,0.00003642969],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003812634,"about_ca_system_score_gemma":0.00860987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002989827,"about_ca_topic_score_gemma":0.003297659,"domain_scores_codex":[0.995828,0.0003059835,0.002173977,0.0003818593,0.000745938,0.00056418],"domain_scores_gemma":[0.9961389,0.001002141,0.001426647,0.0002732864,0.00066104,0.0004979536],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2470792,0.002292501,0.6341034,0.0001370633,0.001066259,0.003149974,0.0003356583,0.0006044622,0.00001234254,0.000006255407,0.0007657427,0.1104471],"study_design_scores_gemma":[0.2197688,0.1316202,0.6297591,0.001960963,0.002362977,0.0006151086,0.000304311,0.0006018493,0.0001339537,0.0000643992,0.01235113,0.0004572029],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957981,0.0001309854,0.0001032376,0.001096629,0.0004488404,0.001294898,0.00002954095,0.00004506362,0.001052742],"genre_scores_gemma":[0.9917123,0.0008811789,0.003097324,0.001345948,0.0003290274,0.00009554383,0.00001834424,0.00007747998,0.0024428],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1293277,"threshold_uncertainty_score":0.9970104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09489864755430755,"score_gpt":0.4556505142668498,"score_spread":0.3607518667125422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}